| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Albertine A Scheltema Beduin, Marije Swets, Marise Machielsen, Nikie Korve. Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients. The Journal of clinical psychiatry. vol 73. issue 11. 2013-02-19. PMID:23218156. |
obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients. |
2013-02-19 |
2023-08-12 |
Not clear |
| Albertine A Scheltema Beduin, Marije Swets, Marise Machielsen, Nikie Korve. Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients. The Journal of clinical psychiatry. vol 73. issue 11. 2013-02-19. PMID:23218156. |
to compare the prevalence of obsessive-compulsive symptoms (ocs) in a population of patients with schizophrenia taking clozapine, olanzapine, or risperidone or taking no antipsychotic medication. |
2013-02-19 |
2023-08-12 |
Not clear |
| István Gacsályi, Katalin Nagy, Katalin Pallagi, György Lévay, László G Hársing, Krisztina Móricz, Szabolcs Kertész, Péter Varga, József Haller, Gábor Gigler, Gábor Szénási, József Barkóczy, Judit Bíró, Michael Spedding, Ferenc A Anton. Egis-11150: a candidate antipsychotic compound with procognitive efficacy in rodents. Neuropharmacology. vol 64. 2013-02-11. PMID:22824189. |
the introduction of atypical antipsychotics such as risperidone, olanzapine and clozapine has obviated this problem, but none of the current drugs seem to improve the cognitive deficits accompanying schizophrenia. |
2013-02-11 |
2023-08-12 |
mouse |
| Itaru Miura, Satoshi Takeuchi, Akihiko Katsumi, Keiko Kanno, Kenya Watanabe, Hirobumi Mashiko, Shin-Ichi Niw. Effect of switching to risperidone after unsuccessful treatment with aripiprazole on plasma monoamine metabolites level in the treatment of acute schizophrenia. Human psychopharmacology. vol 27. issue 5. 2013-02-05. PMID:22927115. |
effect of switching to risperidone after unsuccessful treatment with aripiprazole on plasma monoamine metabolites level in the treatment of acute schizophrenia. |
2013-02-05 |
2023-08-12 |
Not clear |
| Itaru Miura, Satoshi Takeuchi, Akihiko Katsumi, Keiko Kanno, Kenya Watanabe, Hirobumi Mashiko, Shin-Ichi Niw. Effect of switching to risperidone after unsuccessful treatment with aripiprazole on plasma monoamine metabolites level in the treatment of acute schizophrenia. Human psychopharmacology. vol 27. issue 5. 2013-02-05. PMID:22927115. |
we investigated the effects of risperidone on plasma levels of homovanillic acid (hva) and 3-methoxy-4hydroxyphenylglycol after unsuccessful aripiprazole treatment in acute schizophrenia. |
2013-02-05 |
2023-08-12 |
Not clear |
| Hidenobu Suzuki, Keishi Ge. The influence of switching from haloperidol decanoate depot to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia. Human psychopharmacology. vol 27. issue 5. 2013-02-05. PMID:23001955. |
the influence of switching from haloperidol decanoate depot to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia. |
2013-02-05 |
2023-08-12 |
Not clear |
| Hidenobu Suzuki, Keishi Ge. The influence of switching from haloperidol decanoate depot to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia. Human psychopharmacology. vol 27. issue 5. 2013-02-05. PMID:23001955. |
this study was a comparative investigation of the effects on clinical symptoms and cognitive function of switching the treatment of schizophrenia patients from haloperidol decanoate depot to risperidone long-acting injection (rlai) compared with a control group that continued receiving haloperidol decanoate depot. |
2013-02-05 |
2023-08-12 |
Not clear |
| b' Tihomir Stojkovi\\xc4\\x87, Nevena V Radonji\\xc4\\x87, Milica Velimirovi\\xc4\\x87, Gordana Jevti\\xc4\\x87, Vera Popovi\\xc4\\x87, Mirjana Dokni\\xc4\\x87, Nata\\xc5\\xa1a D Petronijevi\\xc4\\x8. Risperidone reverses phencyclidine induced decrease in glutathione levels and alterations of antioxidant defense in rat brain. Progress in neuro-psychopharmacology & biological psychiatry. vol 39. issue 1. 2013-01-21. PMID:22735395.' |
further studies are necessary in order to clarify the significance of risperidone influence on oxidative stress parameters in schizophrenia. |
2013-01-21 |
2023-08-12 |
rat |
| Hoda Moteshafi, Emmanuel Sti. Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis. Expert opinion on drug safety. vol 11. issue 5. 2013-01-21. PMID:22913713. |
comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis. |
2013-01-21 |
2023-08-12 |
Not clear |
| George Bartzokis, Po H Lu, Erika P Raven, Chetan P Amar, Nicole R Detore, Alexander J Couvrette, Jim Mintz, Joseph Ventura, Laurie R Casaus, John S Luo, Kenneth L Subotnik, Keith H Nuechterlei. Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia. Schizophrenia research. vol 140. issue 1-3. 2013-01-18. PMID:22809684. |
impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia. |
2013-01-18 |
2023-08-12 |
Not clear |
| Larry Alphs, William H Olson, Ibrahim Turkoz, John Fastenau, Joseph Huliha. Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia. The Journal of clinical psychiatry. vol 73. issue 10. 2013-01-17. PMID:23140655. |
cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia. |
2013-01-17 |
2023-08-12 |
Not clear |
| Norio Yasui-Furukori, Ayako Kaneda, Norio Sugawara, Tetsu Tomita, Sunao Kanek. Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients. Journal of psychopharmacology (Oxford, England). vol 26. issue 6. 2013-01-15. PMID:21616975. |
this study administered aripiprazole or placebo to 36 outpatients with schizophrenia also receiving risperidone or olanzapine for 12 weeks in a double-blind, randomized, placebo-controlled study. |
2013-01-15 |
2023-08-12 |
Not clear |
| Zhiyun Wei, Lei Wang, Mengmeng Zhang, Jiekun Xuan, Yang Wang, Baocheng Liu, Liyan Shao, Jun Li, Zhen Zeng, Tao Li, Jie Liu, Ti Wang, Ming Zhang, Shengying Qin, Yifeng Xu, Guoyin Feng, Lin He, Qinghe Xin. A pharmacogenetic study of risperidone on histamine H3 receptor gene (HRH3) in Chinese Han schizophrenia patients. Journal of psychopharmacology (Oxford, England). vol 26. issue 6. 2013-01-15. PMID:21652606. |
a pharmacogenetic study of risperidone on histamine h3 receptor gene (hrh3) in chinese han schizophrenia patients. |
2013-01-15 |
2023-08-12 |
human |
| Zhiyun Wei, Lei Wang, Mengmeng Zhang, Jiekun Xuan, Yang Wang, Baocheng Liu, Liyan Shao, Jun Li, Zhen Zeng, Tao Li, Jie Liu, Ti Wang, Ming Zhang, Shengying Qin, Yifeng Xu, Guoyin Feng, Lin He, Qinghe Xin. A pharmacogenetic study of risperidone on histamine H3 receptor gene (HRH3) in Chinese Han schizophrenia patients. Journal of psychopharmacology (Oxford, England). vol 26. issue 6. 2013-01-15. PMID:21652606. |
we genotyped tag single nucleotide polymorphisms (snps) of the hrh3 gene (rs3787429 and rs3787430) and analyzed their association with the reduction of brief psychiatric rating scale (bprs) score in chinese han schizophrenia patients (n = 129), following an eight-week period of risperidone monotherapy. |
2013-01-15 |
2023-08-12 |
human |
| Angelika Mehnert, Deborah Nicholl, Hanna Pudas, Monique Martin, Alistair McGuir. Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden. Journal of medical economics. vol 15. issue 5. 2013-01-14. PMID:22458756. |
cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in sweden. |
2013-01-14 |
2023-08-12 |
Not clear |
| Angelika Mehnert, Deborah Nicholl, Hanna Pudas, Monique Martin, Alistair McGuir. Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden. Journal of medical economics. vol 15. issue 5. 2013-01-14. PMID:22458756. |
to model the cost effectiveness of paliperidone palmitate (paliperidone long-acting injectable; plai), a new once-monthly long-acting antipsychotic therapy, compared with risperidone long-acting injectable (rlai) and olanzapine pamoate (olai), in multi-episode patients (two or more relapses) with schizophrenia in sweden. |
2013-01-14 |
2023-08-12 |
Not clear |
| Leslie Citrome, Zhenchao Guo, Iftekhar Kalsekar, Robert A Forbes, Tony Hebde. Trends in combination antipsychotic use among persons with commercial insurance: a data snapshot. Innovations in clinical neuroscience. vol 9. issue 3. 2013-01-10. PMID:22567605. |
although all three diagnostic groups were associated with varying amounts of combination antipsychotic use that included aripiprazole, olanzapine, quetiapine, risperidone and ziprasidone, persons with schizophrenia exhibited the highest rates. |
2013-01-10 |
2023-08-12 |
Not clear |
| Jorge A Quiroz, Sarah Rusch, An Thyssen, Joseph M Palumbo, Stuart Kushne. Deltoid injections of risperidone long-acting injectable in patients with schizophrenia. Innovations in clinical neuroscience. vol 8. issue 6. 2013-01-09. PMID:21779538. |
deltoid injections of risperidone long-acting injectable in patients with schizophrenia. |
2013-01-09 |
2023-08-12 |
Not clear |
| Jorge A Quiroz, Sarah Rusch, An Thyssen, Joseph M Palumbo, Stuart Kushne. Deltoid injections of risperidone long-acting injectable in patients with schizophrenia. Innovations in clinical neuroscience. vol 8. issue 6. 2013-01-09. PMID:21779538. |
risperidone long-acting injectable was previously approved for treatment of schizophrenia as biweekly injections in the gluteal muscle only. |
2013-01-09 |
2023-08-12 |
Not clear |
| Srihari Gopal, Gahan Pandina, Rosanne Lane, Isaac Nuamah, Bart Remmerie, Danielle Coppola, David Houg. A Post-hoc comparison of paliperidone palmitate to oral risperidone during initiation of long-acting risperidone injection in patients with acute schizophrenia. Innovations in clinical neuroscience. vol 8. issue 8. 2013-01-09. PMID:21922067. |
a post-hoc comparison of paliperidone palmitate to oral risperidone during initiation of long-acting risperidone injection in patients with acute schizophrenia. |
2013-01-09 |
2023-08-12 |
Not clear |